Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) announced that Magdalena Biosciences, a joint venture held through its wholly owned subsidiary Filament Health Corp., has reported positive results from a preclinical study involving a coca leaf extract as a potential weight management therapy following GLP-1 drug cessation.

The 20-day study, conducted in Alberta, Canada, in collaboration with the Borgland Lab at the University of Calgary, found that a novel extract derived from coca leaves prevented weight gain in mice placed on a high-fat diet, without reducing food intake or increasing physical activity. Stephanie Borgland, PhD, served as principal investigator.

Magdalena intends to develop the coca leaf extract as a prescription drug candidate under the U.S. Food and Drug Administration's Botanical Guidance. The extract is being evaluated for use as a weight maintenance therapy after patients stop taking GLP-1 medications, a class of drugs that reduce appetite while in use but whose effects diminish upon discontinuation.

The coca leaf used in the research was supplied by Empresa Nacional de La Coca (ENACO), a Peruvian state company, under an Internationally Recognized Certificate of Compliance consistent with the Nagoya Protocol requirements of Peru.

Magdalena Biosciences was formed in 2023 by Filament Health and Jaguar Health, Inc. (NASDAQ: JAGX). Boulder, Colorado-based One Small Planet has committed $1,000,000 in funding to the venture.

"This is an encouraging early result from Magdalena Biosciences and a clear example of the broader value created through our acquisition of Filament," said Todd Shapiro, chief executive officer and director of Red Light Holland. "We look forward to supporting Magdalena and our partners at Jaguar as this candidate advances under the FDA's Botanical Guidance."

Preclinical results in animals are not necessarily predictive of outcomes in human clinical trials, and the drug candidate has not yet received regulatory approval.